Introduction
============

Atrial fibrillation (AF) is a frequent arrhythmia with an estimated prevalence of 1.5--2% in developed countries.[@b1],[@b2] The occurrence is suspected to rise due to an ageing population and the progressive nature of the arrhythmia.[@b2]--[@b6] Besides, AF is associated with increased morbidity, mortality, and risk of thromboembolism, which can be significantly reduced with oral anticoagulation.[@b2],[@b7]--[@b11] The CHADS~2~- (Congestive Heart failure, hypertension, Age \>75 years, Diabetes, Stroke \[doubled\]) and CHA~2~DS~2~VASc- (Congestive Heart failure, hypertension, Age ≥ 75 years \[doubled\], Diabetes, Stroke \[doubled\], Vascular disease, Age 65-74 years, Sex category \[female sex\]) score have been established to guide antithrombotic therapy in individuals with known AF.[@b8],[@b12],[@b13] However, AF is often not diagnosed until patients present with thromboembolic complications.[@b1],[@b2],[@b11],[@b14] In up to 25% of patients, AF is suspected to be the cause of a cryptogenic stroke.[@b11],[@b14] Therefore, early identification of individuals with AF seems to be warranted in order to prevent associated complications.[@b1],[@b8]

Many efforts have been undertaken to create models for the identification of patients at risk of AF before complications become apparent. So far, risk stratification has been limited to small cohorts or restricted age groups. Finally, risk stratification was not easily adopted in daily practice.[@b3],[@b15] The CHADS~2~- and CHA~2~DS~2~VASc-score are well-established tools to estimate the risk of thromboembolic events in individuals with known AF.[@b1],[@b8],[@b12],[@b13] Some features of these scores are not only used to predict the risk of thromboembolic complications, but also to predict the occurrence of AF.[@b3],[@b8],[@b15]

In this study, we hypothesized that the CHADS~2~- and CHA~2~DS~2~VASc-score may predict the prevalence of AF and may be used to guide cardiac monitoring.

Methods
=======

A total of 150,408 patients who were referred to different medical departments in the University Hospital of Rostock between January 1, 2007 and December 31, 2012 were included in this study. The CHADS~2~- and CHAD~2~DS~2~VASc-scores were prospectively and electronically documented using the International Statistical Classification of Diseases, 10th Revision (ICD-10) codes: Hypertension (ICD-10 codes I10--I15), previous transient ischemic attack (TIA), stroke or arterial thromboembolism (ICD-10 codes G45.9, I63.0--I63.9, and I74--I74.9), congestive heart failure (ICD-10 codes I50.00--I50.01, I50.9, I50.11--I50.14, and I50.19 ), and diabetes (ICD-10 codes E10.0--E14.91). In addition, vascular diseases such as myocardial infarction (ICD-10 codes I21.0--I21.9, I22.0--I22.9, and I25.20--I25.29), coronary artery disease (ICD-10 codes I25.0--I25.19), peripheral arterial occlusive disease (ICD-10 codes I70.2--I70.25), or atherosclerosis of the aorta (ICD-10 code I70.0) were documented. Age at the time of admission and gender were also recorded in all patients. Based on this data, the CHADS~2~- and CHA~2~DS~2~VASc-score was calculated for each patient. Finally, patients were identified with an admission code of AF (ICD-10 codes I48.0--I48.2, and I48.9) based on anamnestic data, electrocardiogram (ECG)-recording, Holter monitoring, and data from cardiac devices. Precisely, in patients with anamnestic AF there had to be at least one ECG with documented AF before hospitalization, based on a physician recall. In patients with first detected AF during the hospital stay, we used ECG recording, Holter monitoring, and also data from loop recorders and cardiac devices for the diagnosis of AF. An episode of AF was defined as an event lasting greater than 30 seconds in duration. Patients with paroxysmal as well as persistent AF were included in our study.

Statistical Analysis
--------------------

All data were stored and analyzed using the SPSS statistical package 21.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were computed for continuous and categorical variables. The statistics computed included mean and standard deviation (SD) of continuous variables and are presented as mean ± SD, frequencies, and relative frequencies of categorical factors.

Comparisons between groups for categorical variables were done using the χ^2^ or Fisher\'s exact test and for continuous variables using a *t*-test for independent samples. The logistic regression model was used to evaluate the influence of several factors constituting the scores on risk for AF. Evaluation was done by computation of odds ratios (OR), 95% confidence intervals (95% CI), and examination the significance of the Wald statistic. All P values resulted from two-sided statistical tests and values of P \< 0.05 were considered to be statistically significant.

Results
=======

A total of 150,408 patients were included in the study; mean age was 67.6 ± 13.6 years (Table[1](#tbl1){ref-type="table"}). A total of 46,602 patients (31%) were between 65 years and 74 years and 51,720 older than 74 years of age (34.4%, Table[1](#tbl1){ref-type="table"}). The majority (56.9%) were male. AF was known in 23,905 patients (15.9%) with a mean age of 72.8 ± 10.5 years (Table[1](#tbl1){ref-type="table"}). Of 150,408 patients, 80.2% suffered from hypertension. Diabetes mellitus was present in 35.3% and vascular diseases in 30.4% of patients. Congestive heart failure was documented in 10.2%, a history of TIA or stroke in 4.0% of patients.

###### 

Baseline Characteristics

                                                  Without AF           With AF              
  -------------------------- ------------- ------ ------------- ------ ------------- ------ ---------
  Patients                   150,408       100    126,503       84.1   23,905        15.9   
  Age (mean ± SD) years      67.6 ± 13.6          66.6 ± 13.9          72.8 ± 10.5          \<0.001
  Age \<65 years             52,086        34.6   47,577        37.6   4,544         19.0   
  Age 65--74 years           46,602        31.0   38,994        30.8   7,608         31.8   
  Age \>74 years             51,720        34.4   39,932        31.6   11,753        49.2   
  Age \>75 years             46,286        30.8   35,567        28.1   10,665        44.6   
  Female                     64,835        43.1   54,748        43.3   10,087        42.2   0.002
  Congestive heart failure   15,326        10.2   9,932         7.9    5,394         22.6   \<0.001
  Hypertension               120,631       80.2   102,830       81.3   17,801        74.5   \<0.001
  Diabetes mellitus          53,115        35.3   44,236        35.0   8,879         37.1   \<0.001
  History of stroke          5,984         4.0    4,302         3.4    1,682         7.0    \<0.001
  Vascular disease           45,755        30.4   36,603        28.9   9,152         38.3   \<0.001

AF = atrial fibrillation; SD = standard deviation.

CHADS~2~-Score
--------------

The mean CHADS~2~-score was 1.65 ± 0.92. The prevalence of AF was 10.1%, 15.5%, 25.8%, 37.4%, 45.9%, and 54.2% in patients with a CHADS~2~-score between 1 and 6, respectively (Table[2](#tbl2){ref-type="table"}, Fig.[1](#fig01){ref-type="fig"}). This prevalence of AF increased continuously and significantly by 5.4--11.5% with every score point (P \< 0.001).

###### 

Prevalence of Atrial Fibrillation with Increasing CHADS~2~-Score and Main Reason for Hospitalization

                 Prevalence of AF (%)                                       
  -------------- ---------------------- ------ ------ ------ ------ ------- ------
  1              10.1                   21.2   10.7   6.0    6.2    3.7     3.0
  2              15.5                   26.2   17.1   15.0   10.8   7.9     4.3
  3              25.8                   36.7   29.4   22.7   19.0   13.8    5.8
  4              37.4                   45.2   40.6   32.2   36.7   22.9    75.0
  5              45.9                   60.0   35.7   44.9   68.0   28.6    25.0
  6              54.2                   38.5   20.0   57.1   88.9   100.0   0
  Mean ± SD^‡^   1.65 ± 0.92                                                

CHADS~2~-Score = Congestive Heart failure, hypertension, Age \>75 years, Diabetes, Stroke (doubled); SD = standard deviation.
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The rising prevalence of AF with an increasing CHADS~2~-score was present in the whole cohort irrespective of the medical department patients were admitted to and the underlying disease that caused the hospitalization (Table[2](#tbl2){ref-type="table"}). The prevalence was highest in patients who were admitted to cardiology and cardiac surgery because AF was the reason for admission in many patients. Still, the prevalence increased with an increasing score. Overall, the prevalence of AF was significantly increased in patients older than 74 years of age (OR = 2.09, 95% CI: 2.04--2.15), with congestive heart failure (OR = 3.42, 95% CI: 3.30--3.55), diabetes mellitus (OR = 1.10, 95% CI: 1.07--1.13), and a history of stroke (OR = 2.12, 95% CI: 2.00--2.24; Table[3](#tbl3){ref-type="table"}). Surprisingly, the prevalence of AF was lower in patients with hypertension (OR = 0.67, 95% CI: 0.65--0.69; Table[3](#tbl3){ref-type="table"}).

###### 

Prevalence of Atrial Fibrillation and Factors Constituting the CHADS~2~-Score and the CHA~2~DS~2~VASc-Score

  Variable                   Odds Ratio   95% CI       P Value
  -------------------------- ------------ ------------ ---------
  \>74 years                 2.09         2.04--2.15   \<0.001
  Congestive heart failure   3.42         3.30--3.55   \<0.001
  Hypertension               0.67         0.65--0.69   \<0.001
  Diabetes mellitus          1.10         1.07--1.13   \<0.001
  History of stroke          2.12         2.00--2.24   \<0.001
  Female sex                 0.96         0.93--0.98   \<0.001
  Vascular disease           1.52         1.48--1.57   \<0.001

CHA2DS2VASc-Score = Congestive Heart failure, hypertension, Age 75 years (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65-74 years, Sex category (female sex); CI = confidence intervals. Other abbreviations as in previous tables.

The prevalence of stroke increased from 0% to 93.8% between a CHADS~2~-score of 1 and 6 (Table[4](#tbl4){ref-type="table"}). Up to a score of 3, the prevalence of stroke was higher in patients with known AF. Beyond a score of 3, patients showed a high prevalence of stroke irrespective of AF (Table[4](#tbl4){ref-type="table"}).

###### 

Prevalence of Stroke and CHADS~2~-Score

               Prevalence of   
  --- -------- --------------- ------
  0   7,782    0               0
  1   68,288   0               0
  2   50,534   1.5             9.7
  3   17,918   11.0            20.1
  4   4,856    47.0            32.8
  5   934      96.5            46.2
  6   96       93.8            55.6

Abbreviations as in previous tables.

CHA~2~DS~2~VASc-Score
---------------------

The mean CHA~2~DS~2~VASc-score was 3.04 ± 1.42 in the whole cohort. The prevalence of AF increased progressively and significantly from 9.9% in patients with a CHA~2~DS~2~VASc-score of 1--71.4% in patients with a CHA~2~DS~2~VASc-score of 9 (P \< 0.001, Table[5](#tbl5){ref-type="table"}, Fig.[1](#fig01){ref-type="fig"}). The increasing prevalence of AF in patients with increasing CHA~2~DS~2~VASc-scores was apparent in all medical departments and irrespective of the underlying disease that lead to the hospitalization (Table[5](#tbl5){ref-type="table"}, Fig.[2](#fig02){ref-type="fig"}).

###### 

Prevalence of Atrial Fibrillation with Increasing CHA~2~DS~2~VASc-Score and Main Reason for Hospitalization

              Prevalence of AF (%)                                      
  ----------- ---------------------- ------ ------ ------ ------ ------ ------
  1           9.9                    31.9   9.1    4.7    5.0    2.7    3.1
  2           9.9                    20.6   10.5   6.4    6.7    4.5    3.4
  3           14.2                   23.0   16.5   12.0   10.1   8.1    3.9
  4           17.4                   25.3   20.5   17.4   11.9   9.3    4.7
  5           25.8                   30.6   29.5   26.0   19.0   11.3   6.9
  6           35.5                   35.8   35.6   37.3   30.8   20.8   20.0
  7           47.6                   47.9   46.7   48.0   46.9   40.0   50.0
  8           50.2                   41.2   23.5   50.3   80.0   100    100
  9           71.4                   50.0   100    77.8   100    0      0
  Mean ± SD   3.04 ± 142                                                

Abbreviations as in previous tables.
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Comparable to the CHADS~2~-score the prevalence of AF was also higher in cardiology and cardiac surgery patients and increased with an increasing score. The logistic regression analyses of factors constituting the CHA~2~DS~2~VASc-score revealed the same results for age, congestive heart failure, diabetes mellitus, history of stroke, and hypertension as the CHADS~2~-score (Table[3](#tbl3){ref-type="table"}). In addition, female patients had a slightly decreased prevalence of AF compared with males (OR = 0.96, 95% CI: 0.93--0.98). Patients with vascular disease had an increased relative risk of AF (OR = 1.52, 95% CI: 1.48--1.57) (Table[3](#tbl3){ref-type="table"}).

The prevalence of stroke rose from zero to a maximum of 96.4% between CHA~2~DS~2~VASc-score 1 and 9 (Table[6](#tbl6){ref-type="table"}). Up to a score of 6, the prevalence of stroke was higher in patients with AF. Beyond a score of 6, the prevalence of stroke was high irrespective of AF.

###### 

Prevalence of Stroke and CHA~2~DS~2~VASc-Score

      Prevalence of Stroke          
  --- ---------------------- ------ ------
  0   1,425                  0      0
  1   20,047                 0      0
  2   36,246                 0.8    5.2
  3   38,171                 2.0    8.7
  4   32,064                 3.4    17.1
  5   15,308                 9.1    25.9
  6   5,475                  25.6   37.3
  7   1,394                  57.2   49.1
  8   249                    96.8   51.0
  9   28                     96.4   70.4

Abbreviations as in previous tables.

Discussion
==========

Prevalence of AF
----------------

The prevalence of AF was 15.9% in our study population (mean age of 67.6 ± 13.6 years). In the general population aged over 65 years, the prevalence of AF is estimated to be between 6% and 8%.[@b5],[@b16],[@b17] One reason for the higher prevalence in our study may be that many patients have been presented to our hospital for AF as reflected in the high prevalence of AF in patients who were admitted to "the cardiology-" or cardiac surgery department. Besides, patients revealed considerable comorbidities as depicted by a mean CHADS~2~-score of 1.65 ± 0.92 and the mean CHA~2~DS~2~VASc-score of 3.04 ± 1.42. However, the increasing prevalence of AF with higher scores was apparent in all departments and independent of the reason for hospitalization. In addition, a prevalence of AF with up to 30--34% has been described in patients with intensified monitoring with implanted devices during a follow up of 1.1--2.5 years.[@b18],[@b19] In line with our data Engdahl et al. reported a prevalence of 14% in a population of 75 years and 76 years of age using a special screening program.[@b20]

The Prevalence of AF and Thromboembolic Complications
-----------------------------------------------------

In patients with known AF risk factors for stroke have been investigated in detail and "resulted in the widely accepted" CHADS~2~- and CHA~2~DS~2~VASc-score to identify patients who may benefit from oral anticoagulation.[@b8] But little is known about the occurrence of AF in patients with stroke risk factors.[@b19]--[@b22]

We could demonstrate that the prevalence of AF rises significantly with every CHADS~2~- and CHA~2~DS~2~VASc-score point, independent of the attending medical department and the underlying disease that lead to hospitalization. Patients with a CHADS2-score of 5 and 6 had AF in 45.9% and 54.2%, respectively. Patients with a CHA2DS2VASc-score between 6 and 9 had AF in 35.3% to 71.4%. In contrast to our study, Ziegler et al. detected AF in 30% of patients during a mean follow-up of 1.1 year with implantable loop recorders.[@b18] The occurrence of AF was not related to underlying CHADS~2~-score and the diagnosis was based on any episode of AF irrespective of symptoms. However, AF lasting longer than 6 hours/day was associated with a higher CHADS~2~-score.[@b18] This may indicate that the scores predict persistent and longer lasting episode of AF rather than short episodes of paroxysmal AF. In addition, Zuo et al. demonstrated that in patients without documented AF but arrhythmic symptoms, a high CHADS~2~- and CHA~2~DS~2~VASc-score was associated with a high risk of a new onset of AF.[@b23]

In patients with CHADS~2~-score of more than 4 and a CHA~2~DS~2~VASc-score of more than 7 the prevalence of stroke was high and independent of AF.

In contrast, the prevalence of thromboembolic complications was two to five times higher with CHADS~2~-score below 4 and CHA~2~DS~2~VASc-score below 7, if AF was present.

We, therefore, conclude that using the CHADS~2~- and CHA~2~DS~2~VASc-score it may be possible to detect patients with a high risk of AF and thromboembolic complications if AF is present. With very high scores the risk of thromboembolic complications may no longer be dependent on AF. While intensified monitoring may be warranted in the former patients, anticoagulation may be warranted in the latter. This hypothesis should be tested in a prospective trial, which is underway in collaboration with Biotronik (Cleopatra Trial; Biotronik GmbH, Berlin, Germany). In this randomized trial, patients postmyocardial infarction with a CHADS~2~-score of more than 2 undergo intensified monitoring with an implantable loop recorder.

Limitations
-----------

The study was carried out in a single community and there may be a selection bias, because all patients were referred to our hospital for various clinical reasons. However, the relationship between the prevalence of AF and the CHADS~2~- or CHA~2~DS~2~VASc-score was present in all departments irrespective of the reason for referral. In addition, these data were primarily collected to generate reimbursement from health insurances and not primarily for medical reasons. Clinical details such as the severity of AF were not documented. Furthermore, information concerning medication was not available. Nevertheless, in Germany under- and overcoding of diseases is under penalty, so documented data are expected to be very reliable.

Apart from that, in our study population the prevalence of AF was lower among hypertensive patients, although hypertension is considered to be a risk factor for the development of AF. We realized that the population of the eastern part of Germany has many chronic illnesses. The very fact that hypertension was prevalent in 80% of the study patients shows that concerning this disease the study patients are not comparable to general population.

Conclusion
==========

The prevalence of AF increased considerably with increasing CHADS~2~- and CHA~2~DS~2~VASc-scores. The prevalence of thromboembolic complications was dependent on the presence of AF up to a CHADS~2~-score of 3 and CHA~2~DS~2~VASc-score of 6. This should warrant intensified monitoring in these patients. The prevalence of thromboembolic complications was high and independent of the presence of AF in patients with a CHADS~2~-score of 4 or more and CHA~2~DS~2~VASc-score of 7 or more. This may indicate that the need for anticoagulation may be independent of the documentation of AF. Both hypotheses should be prospectively verified.
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